LY255582

LY255582 is a pan-opioid antagonist and has high affinity for mu, delta, and kappa receptors (Ki: 0.4 nM, 5.2, 2.0 nM respectively) . LY255582 can decrease food intake and body weight. LY255582 can be used for the research of obesity[1][2][3][4].

Product Specifications

CAS Number

[119193-09-8]

UNSPSC

12352005

Target

Opioid Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/ly255582.html

Purity

98.0

Solubility

DMSO : 15 mg/mL (ultrasonic; warming)

Smiles

OC1=CC([C@]2([C@H](CN(CC2)CC[C@@H](C3CCCCC3)O)C)C)=CC=C1

Molecular Formula

C22H35NO2

Molecular Weight

345.52

References & Citations

[1]Levine AS, et al. Central administration of the opioid antagonist, LY255582, decreases short- and long-term food intake in rats. Brain Res. 1991 Dec 6;566 (1-2) :193-7. |[2]Need AB, et al. In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously. Life Sci. 2007 Oct 13;81 (17-18) :1389-96. |[3]S.L. Gackenheimer, et al. Localization of opioid receptor antagonist [3H]-LY255582 binding sites in mouse brain: Comparison with the distribution of mu, delta and kappa binding sites. Neuropeptides. 2005. 39 (6), 559-567. |[4]Shaw WN, et al. Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants. Pharmacol Biochem Behav. 1993 Nov;46 (3) :653-9. |[5]Chen DT, et al. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target. Br J Anaesth. 2019 Jun;122 (6) :e157-e167.